WallStSmart

Agilent Technologies Inc (A)vsDanaher Corporation (DHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 247% more annual revenue ($25.11B vs $7.23B). A leads profitability with a 19.6% profit margin vs 16.0%. DHR appears more attractively valued with a PEG of 1.15. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

DHR

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-71.6%)

Margin of Safety

-71.6%

Fair Value

$75.11

Current Price

$139.20

$64.09 premium

UndervaluedFair: $75.11Overvalued
DHRSignificantly Overvalued (-66.7%)

Margin of Safety

-66.7%

Fair Value

$117.88

Current Price

$199.63

$81.75 premium

UndervaluedFair: $117.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

DHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
59.7%10/10

Earnings expanding 59.7% YoY

Market CapQuality
$125.93B9/10

Large-cap with strong market position

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
27.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

DHR2 concerns · Avg: 3.5/10
P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : DHR

The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Return on Equity.

Key Dynamics to Monitor

A carries more volatility with a beta of 1.25 — expect wider price swings.

A is growing revenue faster at 10.0% — sustainability is the question.

DHR generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

A scores higher overall (71/100 vs 66/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Want to dig deeper into these stocks?